Clinical Trials Logo

Neurofibroma, Plexiform clinical trials

View clinical trials related to Neurofibroma, Plexiform.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05825365 Withdrawn - Clinical trials for Neurofibromatosis Type 1

Selumetinib in Chinese Paediatric With Post-operative NF1-PNs, Phaseâ…¡, Double-Blinded, Placebo-Controlled Study

PROTECT
Start date: August 31, 2023
Phase: Phase 2
Study type: Interventional

This is a phase II, multicenter, randomised, parallel, double-blind, placebo-controlled study assessing the efficacy and safety of the MEKi selumetinib compared with placebo in Chinese paediatric participants with post-operative NF1-associated PNs.

NCT ID: NCT03688568 Withdrawn - Clinical trials for Neurofibroma, Plexiform

Study of Imatinib in Children With Neurofibromatosis and Airway Tumors

Start date: September 1, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to look at a subset of plexiform neurofibromas and determine if the airway tumors are more sensitive to imatinib therapy. Funding Source - FDA OOPD

NCT ID: NCT03027401 Withdrawn - Neoplasms Clinical Trials

Clinical Sequencing of Cancer and Tissue Repository: OncoGenomics

Start date: January 10, 2017
Phase:
Study type: Observational

Background: Saliva, blood, tissue, and cancer contain DNA. DNA makes the "instruction book" for the cells in the body. Cancer is caused by changes in DNA that affect cell function. Researchers want to test DNA of people with tumors. They want to look for genetic changes in tumors that could be targets for treatment. Because DNA can change as cancer changes, more testing may be done at different times. Objectives: To find the DNA changes in cancer that may help guide treatment. To collect samples and data to be used in future studies. Eligibility: People any age with cancer or a pre-cancerous tumor Design: - Participants will be screened with a medical history, physical exam, and blood tests. Participants will give a sample of their tumor. This is usually from a previous procedure. Participants will give a saliva or blood sample. They cannot eat, drink, smoke, or chew gum for 30 minutes before giving saliva. They will spit about 1 teaspoon of saliva into a tube. - Some participants may have a punch biopsy instead. A small instrument will take a small piece of skin. - Researchers will collect data from participants medical records. - Participants will answer questions about their family health history. They will also answer questions about their views on the study, including possible unexpected results. - Extra blood or tissue samples may be taken at other times during the participants' treatment. All samples will be saved in secure ClinOmics freezers to be used in future studies. - Participants will be told by their doctors if any test results affect their health or their cancer treatment.